Connect Biopharma Holdings Limited Ordinary Shares (CNTB)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with whether the business earns money and what protects it. Connect Biopharma is a clinical-stage biotech with 64 employees, developing rademikibart for asthma and COPD. It has no durable moat yet; its value depends on clinical trial outcomes and regulatory decisions, not on recurring sales. The filed numbers show a company that is not commercially established: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $2.8 million and net loss was $17.3 million, or diluted EPS of -$0.27. In fiscal Q1 2026, revenue was $169,000 and net loss was $19.4 million. For FY2025, revenue was only $64,000 and net loss was $55.5 million, versus FY2024 revenue of $26.0 million and net loss of $15.6 million. Revenue is volatile and not recurring: filed quarterly revenue ranges from $16,000 in fiscal Q3 2025 to $2.8 million in fiscal Q2 2026. Trailing free cash flow was -$60.6 million, a -104.8% FCF yield on a $57.9 million market cap. FairStock's Piotroski score is 2/9 and Altman Z-score is -12.66, both pointing to financial fragility. The balance sheet has low debt (D/E 0.02), but cash burn is the real issue. At the 2026-10-13 close of $0.92, P/B is 2.14 and P/E is negative. The 52-week range is $0.85-$3.82. FairStock score is 26/100. This is a lottery-like early-stage biotech, not a Graham-style bargain unless one can underwrite the science. I would demand a large margin of safety and a clear path to funding and data.

In plain English: Connect Biopharma Holdings Limited is a small drug company testing an antibody medicine called rademikibart for asthma and COPD. It earns very little revenue and keeps losing money, including a $17.3 million net loss in the quarter ended June 30, 2026. At $0.92 a share, the stock is far below its 52-week high of $3.82, but because there are no profits and cash is being spent, the price does not look cheap based on current numbers; it is mainly a bet on future drug results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer